Is SAB Biotherapeutics Stock a Good Investment?
SAB Biotherapeutics Investment Advice | SABSW |
- Examine SAB Biotherapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research SAB Biotherapeutics' leadership team and their track record. Good management can help SAB Biotherapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact SAB Biotherapeutics' business and its evolving consumer preferences.
- Compare SAB Biotherapeutics' performance and market position to its competitors. Analyze how SAB Biotherapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if SAB Biotherapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about SAB Biotherapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in SAB Biotherapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if SAB Biotherapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine SAB Biotherapeutics Stock
Researching SAB Biotherapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company had not issued any dividends in recent years.
To determine if SAB Biotherapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding SAB Biotherapeutics' research are outlined below:
| SAB Biotherapeutics is way too risky over 90 days horizon | |
| SAB Biotherapeutics has some characteristics of a very speculative penny stock | |
| SAB Biotherapeutics appears to be risky and price may revert if volatility continues | |
| SAB Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 2.24 M. Net Loss for the year was (42.19 M) with loss before overhead, payroll, taxes, and interest of (25.38 M). | |
| SAB Biotherapeutics generates negative cash flow from operations | |
| SAB Biotherapeutics has a poor financial position based on the latest SEC disclosures |
SAB Biotherapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.58) | (0.55) | |
| Return On Capital Employed | (0.60) | (0.63) | |
| Return On Assets | (0.58) | (0.55) | |
| Return On Equity | (0.85) | (0.80) |
Determining SAB Biotherapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if SAB Biotherapeutics is a good buy. For example, gross profit margin measures SAB Biotherapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of SAB Biotherapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in SAB Biotherapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of SAB Biotherapeutics. Check SAB Biotherapeutics' Beneish M Score to see the likelihood of SAB Biotherapeutics' management manipulating its earnings.
Evaluate SAB Biotherapeutics' management efficiency
The company has return on total asset (ROA) of (0.788) % which means that it has lost $0.788 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.7473) %, meaning that it generated substantial loss on money invested by shareholders. SAB Biotherapeutics' management efficiency ratios could be used to measure how well SAB Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -0.55 in 2025. Return On Capital Employed is likely to drop to -0.63 in 2025. At this time, SAB Biotherapeutics' Other Current Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 327.2 K in 2025, whereas Total Assets are likely to drop slightly above 63.5 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.34 | 7.50 | |
| Tangible Book Value Per Share | 9.34 | 7.50 | |
| Enterprise Value Over EBITDA | 0.30 | 0.31 | |
| Price Book Value Ratio | 0.60 | 0.63 | |
| Enterprise Value Multiple | 0.30 | 0.31 | |
| Price Fair Value | 0.60 | 0.63 | |
| Enterprise Value | -14.6 M | -13.8 M |
Leadership at SAB Biotherapeutics emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta 0.446 |
Basic technical analysis of SAB Stock
As of the 24th of March, SAB Biotherapeutics owns the Standard Deviation of 31.32, semi deviation of 18.2, and Market Risk Adjusted Performance of 12.4. In respect to fundamental indicators, the technical analysis model makes it possible for you to check possible technical drivers of SAB Biotherapeutics, as well as the relationship between them. Please validate SAB Biotherapeutics mean deviation, information ratio, as well as the relationship between the Information Ratio and downside variance to decide if SAB Biotherapeutics is priced fairly, providing market reflects its prevailing price of 0.026900001 per share. As SAB Biotherapeutics appears to be a penny stock we also recommend to double-check its total risk alpha numbers.SAB Biotherapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific SAB Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on SAB Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases SAB Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Eddie Sullivan over a week ago Acquisition by Eddie Sullivan of 1740 shares of SAB Biotherapeutics at 0.88 subject to Rule 16b-3 | ||
Moin Andrew over three weeks ago Acquisition by Moin Andrew of 22115 shares of SAB Biotherapeutics at 1000.0 subject to Rule 16b-3 | ||
Ellias Helen K. over three months ago Discretionary transaction by Ellias Helen K. of 2857142 shares of SAB Biotherapeutics at 0.63 subject to Rule 16b-3 | ||
Moin Andrew over six months ago Discretionary transaction by Moin Andrew of 2747097 shares of SAB Biotherapeutics at 0.63 subject to Rule 16b-3 |
Understand SAB Biotherapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing SAB Biotherapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0896 | |||
| Market Risk Adjusted Performance | 12.4 | |||
| Mean Deviation | 19.43 | |||
| Semi Deviation | 18.2 | |||
| Downside Deviation | 22.87 | |||
| Coefficient Of Variation | 1110.55 | |||
| Standard Deviation | 31.32 | |||
| Variance | 981.18 | |||
| Information Ratio | 0.0919 | |||
| Jensen Alpha | 2.83 | |||
| Total Risk Alpha | 5.19 | |||
| Sortino Ratio | 0.1258 | |||
| Treynor Ratio | 12.39 | |||
| Maximum Drawdown | 214.55 | |||
| Value At Risk | (38.46) | |||
| Potential Upside | 50.19 | |||
| Downside Variance | 523.08 | |||
| Semi Variance | 331.19 | |||
| Expected Short fall | (30.33) | |||
| Skewness | 1.96 | |||
| Kurtosis | 7.54 |
| Risk Adjusted Performance | 0.0896 | |||
| Market Risk Adjusted Performance | 12.4 | |||
| Mean Deviation | 19.43 | |||
| Semi Deviation | 18.2 | |||
| Downside Deviation | 22.87 | |||
| Coefficient Of Variation | 1110.55 | |||
| Standard Deviation | 31.32 | |||
| Variance | 981.18 | |||
| Information Ratio | 0.0919 | |||
| Jensen Alpha | 2.83 | |||
| Total Risk Alpha | 5.19 | |||
| Sortino Ratio | 0.1258 | |||
| Treynor Ratio | 12.39 | |||
| Maximum Drawdown | 214.55 | |||
| Value At Risk | (38.46) | |||
| Potential Upside | 50.19 | |||
| Downside Variance | 523.08 | |||
| Semi Variance | 331.19 | |||
| Expected Short fall | (30.33) | |||
| Skewness | 1.96 | |||
| Kurtosis | 7.54 |
Consider SAB Biotherapeutics' intraday indicators
SAB Biotherapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of SAB Biotherapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 944.77 | |||
| Daily Balance Of Power | 0.2969 | |||
| Rate Of Daily Change | 1.08 | |||
| Day Median Price | 0.0237 | |||
| Day Typical Price | 0.0248 | |||
| Price Action Indicator | 0.0042 | |||
| Period Momentum Indicator | 0.0019 |
SAB Stock media impact
Far too much social signal, news, headlines, and media speculation about SAB Biotherapeutics that are available to investors today. That information is available publicly through SAB media outlets and privately through word of mouth or via SAB internal channels. However, regardless of the origin, that massive amount of SAB data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of SAB Biotherapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of SAB Biotherapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to SAB Biotherapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive SAB Biotherapeutics alpha.
SAB Biotherapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards SAB Biotherapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
SAB Biotherapeutics Corporate Executives
Elected by the shareholders, the SAB Biotherapeutics' board of directors comprises two types of representatives: SAB Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SAB. The board's role is to monitor SAB Biotherapeutics' management team and ensure that shareholders' interests are well served. SAB Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SAB Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward DVM | CoFounder Observer | Profile | |
| Lucy To | EVP CFO | Profile | |
| Michael King | EVP CFO | Profile | |
| Christoph MBA | Executive COO | Profile |
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.